MedTrace Logo

A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

NCT07038005 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2026-02-09

No results posted yet for this study

Summary

This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.

Conditions

  • Advanced Malignant Tumors

Interventions

DRUG

SPGL008

Biological product

Sponsors & Collaborators

  • Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd.

    collaborator UNKNOWN

  • Shenyang Sunshine Pharmaceutical Co., LTD.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-30
Primary Completion
2026-09-22
Completion
2027-06-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07038005 on ClinicalTrials.gov